A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of PBI-4050 on the Pharmacokinetics of Midazolam, a Sensitive Cytochrome P450 3A Substrate, in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2019
Price : $35 *
At a glance
- Drugs Fezagepras (Primary) ; Midazolam
- Indications Acute lung injury; Alstrom's Syndrome; Cystic fibrosis; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Metabolic syndrome; Pulmonary hypertension; Renal fibrosis; Scleroderma; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors ProMetic Life Sciences
- 19 Mar 2019 Status changed from active, no longer recruiting to completed.
- 06 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2018 New trial record